![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: NKIRAS2 |
Gene summary for NKIRAS2 |
![]() |
Gene information | Species | Human | Gene symbol | NKIRAS2 | Gene ID | 28511 |
Gene name | NFKB inhibitor interacting Ras like 2 | |
Gene Alias | KBRAS2 | |
Cytomap | 17q21.2 | |
Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | A0A024R1Z4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
28511 | NKIRAS2 | C30 | Human | Oral cavity | OSCC | 7.40e-39 | 1.58e+00 | 0.3055 |
28511 | NKIRAS2 | C38 | Human | Oral cavity | OSCC | 6.02e-07 | 9.84e-01 | 0.172 |
28511 | NKIRAS2 | C43 | Human | Oral cavity | OSCC | 2.41e-37 | 8.00e-01 | 0.1704 |
28511 | NKIRAS2 | C46 | Human | Oral cavity | OSCC | 1.95e-19 | 5.48e-01 | 0.1673 |
28511 | NKIRAS2 | C51 | Human | Oral cavity | OSCC | 3.15e-08 | 5.20e-01 | 0.2674 |
28511 | NKIRAS2 | C57 | Human | Oral cavity | OSCC | 1.54e-15 | 4.93e-01 | 0.1679 |
28511 | NKIRAS2 | C06 | Human | Oral cavity | OSCC | 2.36e-03 | 9.02e-01 | 0.2699 |
28511 | NKIRAS2 | C08 | Human | Oral cavity | OSCC | 9.06e-26 | 5.51e-01 | 0.1919 |
28511 | NKIRAS2 | C09 | Human | Oral cavity | OSCC | 2.99e-05 | 1.33e-01 | 0.1431 |
28511 | NKIRAS2 | LN46 | Human | Oral cavity | OSCC | 1.54e-12 | 5.59e-01 | 0.1666 |
28511 | NKIRAS2 | SYSMH1 | Human | Oral cavity | OSCC | 3.96e-12 | 3.55e-01 | 0.1127 |
28511 | NKIRAS2 | SYSMH2 | Human | Oral cavity | OSCC | 1.13e-16 | 4.00e-01 | 0.2326 |
28511 | NKIRAS2 | SYSMH3 | Human | Oral cavity | OSCC | 2.94e-14 | 4.14e-01 | 0.2442 |
28511 | NKIRAS2 | SYSMH5 | Human | Oral cavity | OSCC | 4.39e-10 | 2.89e-01 | 0.0647 |
28511 | NKIRAS2 | SYSMH6 | Human | Oral cavity | OSCC | 2.40e-02 | 1.64e-01 | 0.1275 |
28511 | NKIRAS2 | P1_cSCC | Human | Skin | cSCC | 4.11e-16 | 4.25e-01 | 0.0292 |
28511 | NKIRAS2 | P2_cSCC | Human | Skin | cSCC | 3.77e-08 | 2.86e-01 | -0.024 |
28511 | NKIRAS2 | P4_cSCC | Human | Skin | cSCC | 1.23e-12 | 3.30e-01 | -0.00290000000000005 |
28511 | NKIRAS2 | P10_cSCC | Human | Skin | cSCC | 2.62e-07 | 3.01e-01 | 0.1017 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000724919 | Esophagus | ESCC | I-kappaB kinase/NF-kappaB signaling | 183/8552 | 281/18723 | 3.02e-11 | 1.01e-09 | 183 |
GO:00072494 | Liver | Cirrhotic | I-kappaB kinase/NF-kappaB signaling | 108/4634 | 281/18723 | 2.21e-07 | 5.64e-06 | 108 |
GO:000724912 | Liver | HCC | I-kappaB kinase/NF-kappaB signaling | 156/7958 | 281/18723 | 6.66e-06 | 8.00e-05 | 156 |
GO:000724910 | Oral cavity | OSCC | I-kappaB kinase/NF-kappaB signaling | 169/7305 | 281/18723 | 4.69e-13 | 2.25e-11 | 169 |
GO:000724925 | Skin | cSCC | I-kappaB kinase/NF-kappaB signaling | 116/4864 | 281/18723 | 1.33e-08 | 4.08e-07 | 116 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NKIRAS2 | SNV | Missense_Mutation | c.41N>T | p.Ser14Phe | p.S14F | Q9NYR9 | protein_coding | deleterious(0.03) | benign(0.012) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
NKIRAS2 | SNV | Missense_Mutation | c.56C>T | p.Ser19Leu | p.S19L | Q9NYR9 | protein_coding | deleterious(0) | benign(0.201) | TCGA-JW-A5VJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
NKIRAS2 | SNV | Missense_Mutation | c.218G>A | p.Arg73Gln | p.R73Q | Q9NYR9 | protein_coding | deleterious(0.04) | benign(0.18) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
NKIRAS2 | SNV | Missense_Mutation | c.152N>A | p.Arg51Gln | p.R51Q | Q9NYR9 | protein_coding | tolerated(0.07) | possibly_damaging(0.746) | TCGA-AA-A01P-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
NKIRAS2 | SNV | Missense_Mutation | novel | c.58N>G | p.Ile20Val | p.I20V | Q9NYR9 | protein_coding | tolerated(0.36) | benign(0.042) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NKIRAS2 | SNV | Missense_Mutation | novel | c.94N>A | p.Gly32Ser | p.G32S | Q9NYR9 | protein_coding | tolerated(0.19) | possibly_damaging(0.474) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NKIRAS2 | SNV | Missense_Mutation | c.177N>A | p.Phe59Leu | p.F59L | Q9NYR9 | protein_coding | tolerated(0.66) | benign(0.013) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
NKIRAS2 | SNV | Missense_Mutation | c.426G>T | p.Glu142Asp | p.E142D | Q9NYR9 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
NKIRAS2 | SNV | Missense_Mutation | rs147962346 | c.385C>T | p.Arg129Cys | p.R129C | Q9NYR9 | protein_coding | deleterious(0.01) | benign(0.046) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
NKIRAS2 | insertion | Frame_Shift_Ins | rs781916716 | c.151_152insG | p.Val53GlyfsTer9 | p.V53Gfs*9 | Q9NYR9 | protein_coding | TCGA-B5-A11G-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |